<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084759</url>
  </required_header>
  <id_info>
    <org_study_id>J09121, NA_00033419</org_study_id>
    <nct_id>NCT01084759</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer</brief_title>
  <official_title>A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine if men with evidence of progressive prostate
      cancer while on chronic androgen ablation of ≥ 1 year duration will exhibit a clinical
      response following administration of parenteral testosterone and oral etoposide.

      Treatment Plan: Eligible patients will continue on androgen ablative therapy with luteinizing
      hormone-releasing hormone (LHRH) agonist (i.e. Zoladex or Lupron) if not surgically
      castrated. Patients will receive intramuscular injection with testosterone cypionate at a
      dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This dose
      was selected based on data demonstrating that it produces an initial supraphysiologic serum
      level of testosterone (i.e. &gt; 3-5 times normal level) with eugonadal levels achieved at the
      end of two weeks. Beginning the day of the testosterone injection, patients will also receive
      oral etoposide 100 mg/day in divided doses (50 mg q 12h) x 14 days out of 28 days per cycle.
      After 3 months on therapy, patients will have repeat prostate specific antigen (PSA) and
      bone/computed tomography (CT) scans to establish the effect of combined testosterone and
      etoposide treatment on these parameters (i.e. &quot;testosterone effect baseline&quot;). Patients with
      sustained elevations in PSA ≥ 50% above pre-testosterone treatment PSA levels after the
      initial three months of testosterone and etoposide therapy will not receive continued therapy
      and will come off study. Patients with PSA levels less than the peak serum PSA level seen
      over the three month period (PSA decline) or patients with PSA ≤ 50% of pretreatment baseline
      will receive a second 3 month course of monthly testosterone and etoposide therapy until
      evidence of disease progression. Disease progression is defined as a PSA increase above the
      PSA level obtained after 3 months on testosterone treatment over two successive measurements
      2 weeks apart or evidence of new lesions or progression on bone/CT scans compared to baseline
      studies. Patients who respond to initial treatment with testosterone and etoposide and then
      show signs of progression will have the option of retreatment with testosterone alone after a
      period of 3 months or greater off of the original therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on our preclinical data, high levels of androgens can lead to significant growth
      suppressive effects in prostate cancer cells in vitro and in vivo. Mechanistic data in in
      vitro models suggests that this growth suppression may be due to the accumulation of androgen
      induced TOP2B mediated double strand breaks at AR target sites occurring after stimulation of
      prostate cancer cells with high levels of androgens. Provocatively, the number of double
      strand breaks was significantly increased (Figure 3 B) if the cells were treated with
      etoposide, an agent that leads to formation of double strand breaks at TOP2 target sites,
      concurrently with high-dose androgen stimulation. We hypothesize that co-administration of
      testosterone with etoposide could produce high levels of double strand breaks in prostate
      cancer cells, overwhelming DNA repair and survival mechanisms and leading to cancer cell
      death or growth arrest. To test whether this possibility holds promise for therapy of
      advanced prostate cancer, we propose the following clinical trial of parenteral testosterone
      therapy in combination with oral etoposide in men with evidence of progressive prostate
      cancer during chronic androgen ablation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Completing at Least 3 Months of Therapy With a PSA Below Baseline.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>2 years</time_frame>
    <description>Time to a PSA increase above the PSA level obtained after 3 months on testosterone treatment over two successive measurements 2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With RECIST Response (i.e. Complete Response or Partial Response)</measure>
    <time_frame>2 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan or MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Etoposide and Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone injection</intervention_name>
    <description>Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. &gt; 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.</description>
    <arm_group_label>Etoposide and Testosterone</arm_group_label>
    <other_name>Testosterone Cypionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.</description>
    <arm_group_label>Etoposide and Testosterone</arm_group_label>
    <other_name>Etopophos</other_name>
    <other_name>Toposar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Performance status ≤2

          2. Documented adenocarcinoma of the prostate with histologic confirmation

          3. Treated with continuous androgen ablative therapy (either surgical castration or LHRH
             agonist for ≥ 1 year)

          4. Documented castrate level of serum testosterone (&lt;50 ng/dl)

          5. Evidence of rising PSA on two successive dates &gt; 1 month apart

          6. Treatment with ≤ 2 prior chemotherapeutic regimens allowed

          7. Treatment with ≤2 prior second line hormone therapies allowed.

          8. Prior treatment with ketoconazole is allowed.

          9. Patients must be withdrawn from antiandrogens for ≥ 6 weeks and have documented PSA
             increase after the 6 week withdrawal period.

         10. Patients with rising PSA only or ≤ 5 sites of asymptomatic bone metastases and &lt; 10
             total sites of disease including bone and soft tissue documented within 28 days of
             enrollment on trial.

         11. Patients will considered for repeat treatment with testosterone if they meet the
             following criteria:

               1. Had either PSA decline from baseline following treatment with testosterone or had
                  return of PSA levels to pretreatment baseline once serum testosterone reached a
                  castrate level.

               2. Must continue to meet inclusion/exclusion criteria as described above

               3. Must have been off testosterone therapy for ≥ 3 months

               4. Must have castrate level of serum testosterone

               5. Must have evidence of rising PSA on two occasions at least 2 weeks apart

               6. Are allowed to have had additional treatment with up to 2 additional hormonal
                  therapies that include anti-androgens (e.g. flutamide, bicalutamide, nilutamide,
                  enzalutamide), CYP17 inhibitors (e.g. ketoconazole, abiraterone acetate) or other
                  investigational hormonal therapies.

        Exclusion Criteria:

          1. Evidence of disease in sites or extent that, in the opinion of the investigator, would
             put the patient at risk from therapy with testosterone (e.g. femoral metastases with
             concern over fracture risk, spinal metastases with concern over spinal cord
             compression, lymph node disease with concern for ureteral obstruction)

          2. Abnormal liver function (bilirubin, AST, ALT ≥ 2 x upper limit of normal)

          3. Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)

          4. Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Denmeade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto J Pacheco, BA</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting Wang, MS</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>December 17, 2015</results_first_submitted>
  <results_first_submitted_qc>April 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2016</results_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Testosterone</title>
          <description>Men with castration-resistant prostate cancer will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex or Lupron) if not surgically castrated. Patients will receive intramuscular injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoposide and Testosterone</title>
          <description>Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="56" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Specific Antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="1.4" upper_limit="819.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone</title>
          <description>Note: The limit of detection for this assay is 20 ng/dL. Patients with an undetectable testosterone level were assigned a value of 20 ng/dL.</description>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="20" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Gleason Grade (higher grade indicates more pathologic atypia)</title>
          <description>Gleason score was based on clinical interpretation of the needle biopsy specimen or prostatectomy specimen by an expert pathologist.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gleason score 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason score 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason score 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason score 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of continuous androgen deprivation therapy</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" lower_limit="12" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of second line hormonal therapies received</title>
          <description>Second line hormonal therapies were defined as any agent that inhibits androgen receptor (AR) signaling (e.g. AR antagonist, inhibitors of extragonadal testosterone synthesis).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 second line agent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 second line agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 second line agents</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone metastases</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patients with bone metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without bone metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RECIST evaluable soft tissue metastases</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Patients with RECIST evaluable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without RECIST evaluable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Completing at Least 3 Months of Therapy With a PSA Below Baseline.</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Testosterone cypionate 400 mg intramuscular, day 1 of 28; etoposide 100 mg oral daily, days 1-14 of 28. Note: Etoposide is only given for 3, 28-day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Completing at Least 3 Months of Therapy With a PSA Below Baseline.</title>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="20.6" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to PSA Progression</title>
        <description>Time to a PSA increase above the PSA level obtained after 3 months on testosterone treatment over two successive measurements 2 weeks apart.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Testosterone cypionate 400 mg intramuscular, day 1 of 28; etoposide 100 mg oral daily, days 1-14 of 28. Note: Etoposide is only given for 3, 28-day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <description>Time to a PSA increase above the PSA level obtained after 3 months on testosterone treatment over two successive measurements 2 weeks apart.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221" lower_limit="95" upper_limit="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With RECIST Response (i.e. Complete Response or Partial Response)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan or MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Testosterone cypionate 400 mg intramuscular, day 1 of 28; etoposide 100 mg oral daily, days 1-14 of 28. Note: Etoposide is only given for 3, 28-day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With RECIST Response (i.e. Complete Response or Partial Response)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan or MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Men with castration-resistant prostate cancer will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex or Lupron) if not surgically castrated. Patients will receive intramuscular injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <description>Patient died as a result</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Samuel Denmeade</name_or_title>
      <organization>SKCCC at Johns Hopkins</organization>
      <phone>410-955-8875</phone>
      <email>denmesa@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

